Enterprise Value

879.7M

Cash

256.4M

Avg Qtr Burn

-33.83M

Short % of Float

4.01%

Insider Ownership

20.65%

Institutional Own.

60.33%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
obe-cel (AUTO1) (CD19) Details
Acute lymphoblastic leukemia, Cancer, Blood cancer

PDUFA

Approval decision

AUTO4 Details
Peripheral T cell cancer

Phase 1/2

Update

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Leukemia

Phase 1

Update

AUTO6NG Details
Solid tumor/s, Neuroblastoma

Phase 1

Update

AUTO1/22 (CD19 & CD22) Details
Cancer, Leukemia, Acute lymphoblastic leukemia

Phase 1

Update

obe-cel (AUTO1) (CD19) Details
Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas

Phase 1

Update

AUTO5 Details
T-cell lymphoma

Phase 1

Initiation

obe-cel (AUTO1) (CD19) Details
Autoimmune disease, Systemic lupus erythematosus

Phase 1

Initiation

AUTO3 (CD19, CD22) Details
Lymphoma, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued